Grifols (NASDAQ:GRFS) Raised to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Grifols (NASDAQ:GRFSGet Rating) from a sell rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports.

According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “

Other equities analysts have also recently issued reports about the stock. JPMorgan Chase & Co. cut their target price on shares of Grifols from €15.00 ($16.13) to €11.00 ($11.83) in a research note on Tuesday, January 4th. Morgan Stanley started coverage on shares of Grifols in a research report on Friday, April 8th. They set an equal weight rating for the company. Berenberg Bank lowered their price objective on shares of Grifols from €21.60 ($23.23) to €21.40 ($23.01) in a research report on Thursday, March 3rd. Finally, StockNews.com started coverage on shares of Grifols in a research report on Thursday, March 31st. They set a hold rating for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Grifols presently has a consensus rating of Hold and an average target price of $16.20.

GRFS opened at $10.60 on Friday. The stock has a market capitalization of $7.19 billion, a PE ratio of 9.30 and a beta of 0.40. The company’s fifty day moving average is $11.23. Grifols has a fifty-two week low of $10.10 and a fifty-two week high of $19.07. The company has a quick ratio of 0.94, a current ratio of 1.59 and a debt-to-equity ratio of 0.85.

Several institutional investors have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. increased its stake in Grifols by 8,984.6% in the 3rd quarter. First Horizon Advisors Inc. now owns 2,362 shares of the biotechnology company’s stock worth $107,000 after buying an additional 2,336 shares during the period. JJJ Advisors Inc. increased its stake in Grifols by 106.2% in the 4th quarter. JJJ Advisors Inc. now owns 3,880 shares of the biotechnology company’s stock worth $44,000 after buying an additional 1,998 shares during the period. Parallel Advisors LLC increased its stake in Grifols by 367.8% in the 4th quarter. Parallel Advisors LLC now owns 4,360 shares of the biotechnology company’s stock worth $49,000 after buying an additional 3,428 shares during the period. Lindbrook Capital LLC increased its stake in Grifols by 657.5% in the 4th quarter. Lindbrook Capital LLC now owns 5,886 shares of the biotechnology company’s stock worth $66,000 after buying an additional 5,109 shares during the period. Finally, SG Americas Securities LLC purchased a new position in Grifols in the 3rd quarter worth about $130,000. Hedge funds and other institutional investors own 13.83% of the company’s stock.

About Grifols (Get Rating)

Grifols, SA engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases.

Featured Stories

Get a free copy of the Zacks research report on Grifols (GRFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.